Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned an average rating of “Moderate Buy” from the twenty-eight research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $758.4091.

Several analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $615.00 to $700.00 and gave the company an “equal weight” rating in a research note on Thursday, November 20th. Canaccord Genuity Group reiterated a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Jefferies Financial Group upped their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Bank of America raised their price objective on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Finally, Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. Activest Wealth Management boosted its holdings in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $31,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 2.5%

Shares of REGN stock opened at $723.67 on Thursday. The firm’s 50-day simple moving average is $644.26 and its 200-day simple moving average is $586.74. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $800.99. The firm has a market cap of $76.06 billion, a P/E ratio of 17.33, a PEG ratio of 2.15 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.46 earnings per share. As a group, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.